Delivery Order SPE2DR25D1053-SPE2DR26FT701
- Not listed
- The Defense Logistics Agency awarded a $5,834.04 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 ml pen injectors. This non-competitive, firm fixed-price delivery order is set to be completed by September 5, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $4,571.33 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pens on April 23, 2025, with completion scheduled for April 24, 2025. This competitive award, issued on a firm fixed-price basis without set-aside designation, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), valued at...
- The Defense Logistics Agency awarded a $16,652.51 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase requisition under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors. This firm fixed-price delivery order, valued at $35,744.56, is scheduled for completion by September 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made on a competitive basis with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $35,946.82 to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 10 mg/0.5 mL pen injections on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside transaction and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency (DLA) awarded a $1,525.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. The award was completed competitively with no set-aside designation and carries an ultimate completion date of September 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors, with a contract ceiling value of $22,877.40. This is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and represents a non-competitive award. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $14,950.78 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. The contract represents a single delivery order issued under a larger procurement vehicle and carries...
- The Defense Logistics Agency awarded a delivery order valued at $21,523.36 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 12.5 mg/0.5 mL pen injections. The contract, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a firm fixed price delivery order with no set-aside designation. Performance will be executed from AmerisourceBergen's Conshohocken, Pennsylvania facility, which serves as the company's corporate headquarters. This...
- The Defense Logistics Agency awarded a $14,089.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. The award was competitively procured with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT701Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $16,069.64 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors on November 6, 2025, with an ultimate completion date of November 7, 2025. This non-competitive, firm fixed-price delivery order will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child contract under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026 that enables AmerisourceBergen to furnish a broad range of medications and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company maintains an extensive track record of competitively awarded delivery orders under its DLA prime vendor contract, supplying specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains. This award of Zepbound, a GLP-1 receptor agonist diabetes medication, reflects the contractor's role in providing pharmaceutical products to support military personnel and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.1k | 11/6/25 |